NOVEL GENOTYPE IN TWO SIBLINGS WITH 5-α-
REDUCTASE 2 DEFICIENCY: DIFFERENT CLINICAL
COURSE DUE TO THE TIME OF DIAGNOSIS Kocova M1,*, Plaseska-Karanfilska D2, Noveski P2, Kuzmanovska M2 *Corresponding Author: Professor Dr. Mirjana Kocova, University Pediatric Clinic, Department of
Endocrinology & Genetics, M. Tereza 17, Skopje 1000, Republic of North Macedonia. Tel: +389-70-
242-694. Fax: +389-317-6167. E-mail: mirjanakocova@yahoo.com page: 69
|
REFERENCES
1. Mendonca BB, Domenice S, Arnhold IJ, Costa EM.
46,XY Disorders of sex development (DSD). Clin
Endo-crinol (Oxf). 2009; 70(2): 173-187.
2. Hochberg Z, Chayen R, Reiss N, Falik Z, Makler A,
Munichor M, et al. Clinical, biochemical, and genetic
findings in a large pedigree of male and female
patients with 5 alpha-reductase 2 deficiency. J Clin
Endocrinol Metab. 1996; 81(8): 2821-2827.
3. Maimoun L, Philibert P, Cammas B, Audran F,
Bouchard P, Fenichel P, et al. Phenotypical, biological,
and molecular heterogeneity of 5 α-reductase
deficiency: An extensive international experience of
55 patients. J Clin Endocrinol Metab. 2011; 96(2):
296-307.
4. Andersson S, Berman DM, Jenkins EP, Russell DW.
Deletion of steroid 5 α-reductase 2 gene in male
pseudo-hermaphroditism. Nature. 1991; 354(6349):
159-161.
5. Vilchis F, Ramos L, Mendez JP, Benavides S, Canto
P, Chavez B. Molecular analysis of the SRD5A2 in
46,XY subjects with incomplete virilization: The
P212R substitution of the steroid 5 α-reductase 2 may
constitute an ancestral founder mutation in Mexican
patients. J Androl. 2010; 31(4): 358-364.
6. Imperato-McGinley J, Zhu YS. Androgens and male
physiology the syndrome of 5 α-reductase-2 deficiency.
Mol Cell Endocrinol. 2002; 198(1-2): 51-59.
7. Sasaki G, Ogata T, Ishii T, Kosaki K, Sato S, Homma
K, et al. Micropenis and the 5 α-reductase-2 (SRD5A2)
gene: Mutation and V89L polymorphism
analysis in 81 Japanese patients. J Clin Endocrinol
Metab. 2003; 88(7): 3431-3436.
8. Thigpen AE, Davis DL, Gautier T, Imperato-McGinley
J, Russell DW. Brief report: The molecular basis
of steroid 5 α-reductase deficiency in a large Dominican
kindred. N Engl J Med. 1992; 327(17): 1216-
1219.
9. Alswailem MM, Alzahrani OS, Alghofaili L, Qasem
E, Almohanaa M, Alsagheir A, et al. Molecular genetics
and phenotype/genotype correlation of 5-α
reductase deficiency in a highly consanguineous
population. Endocrine. 2019; 63(2): 361-368.
10. M Selveindran N, Syed Zakaria SZ, Jalaludin MY,
Rasat R. Quality of life in children with disorders of
sex development. Horm Res Paediatr. 2017; 88(5):
324-330.
11. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-
Foster J, et al. Standards and guidelines for the interpretation
of sequence variants: A joint consensus
recommendation of the American College of Medical
Genetics and Genomics and the Association for Molecular
Pathology. Genet Med. 2015; 17(5): 405-424.
12. Nicoletti A, Baldazzi L, Balsamo A, Barp L, Pirazzoli
P, Gennari M, et al. SRD5A2 gene analysis in an Italian
population of under-masculinized 46,XY subjects.
Clin Endocrinol (Oxf). 2005; 63(4): 375-380.
13. Avendano A, Paradisi I, Cammarata-Scalisi F, Callea
M. 5-α-Reductase type 2 deficiency: Is there a genotype-
phenotype correlation? A review. Hormones
(Athens). 2018; 17(2): 197-204. 14. Andonova S, Robeva R, Vazharova R, Ledig S,
Grozdanova L, Stefanova E, et al. New territory for
an old disease: 5-α-reductase type 2 deficiency in
Bulgaria. Sex Dev. 2017; 11(1): 21-28.
15. Perry RJ, Novikova E, Wallace AM, Donaldson MD.
Pitfalls in the diagnosis of 5 α-reductase type 2 deficiency
during early infancy. Horm Res Paediatr.
2011; 75(5): 380-382.
16. Chan AO, But BW, Lee CY, Lam YY, Ng KL, Tung
JY, et al. Diagnosis of 5 α-reductase 2 deficiency: Is
measurement of dihydrotestosterone essential? Clin
Chem. 2013; 59(5): 798-806.
17. Hackel C, Oliveira LE, Ferraz LF, Tonini MM, Silva
DN, Toralles MB, et al. New mutations, hotspots,
and founder effects in Brazilian patients with steroid
5 α-reductase deficiency type 2. J Mol Med (Berl).
2005; 83(7): 569-576.
18. Karczewski K, Francioli L. The genome Aggregation
Database (gnomAD). MacArthur Lab. 2017.
(https:// macarthurlab.org/2017/02/27/the-genomeaggregation-
database-gnomad/.)
19. Silveri RI, Russell DW. 5 α-Reductase type 2 mutations
are present in some boys with isolated hypospadias.
J Urol. 1999; 162(3): 1142-1145.
20. Rahimi M, Ghanbari M, Fazeli Z, Rouzrokh M, Omrani
S, Mirfakhraie R, et al. Association of SRD5A2
gene mutations with risk of hypospadias in the Iranian
population. J Endocrinol Invest. 2017; 40(4): 391-396.
21. Samtani R, Bajpai M, Ghosh P, Saraswathy K. SRD5A2
gene mutations – A population-based review.
Pediatr Endocrinol Rev. 2010; 8(1): 34-40.
22. Fang C, Guo ZQ, Chen XY, Liu TZ, Zeng XT, Wang
XH. Relationship between SRD5A2 rs9282858 polymorphism
and the susceptibility of prostate cancer:
A meta-analysis based on 20 publications. Medicine
(Baltimore). 2017; 96(19): e6791.
23. Pearce CL, van den Berg DJ, Makridakis N, Reichardt
JK, Ross RK, Pike MC, et al. No association
between the SRD5A2 gene A49T missense variant
and prostate cancer risk: Lessons learned. Hum Mol
Genet. 2008; 17(16): 2456-2461.
24. Costa EM, Domenice S, Sircili MH, Inacio M, Mendonca
BB. DSD due to 5 α-reductase 2 deficiency –
From diagnosis to long term outcome. Semin Reprod
Med. 2012; 30(5): 427-431.
25. Byers HM, Mohnach LH, Fechner PY, Chen M,
Thomas IH, Ramsdell LA, et al. Unexpected ethical
dilemmas in sex assignment in 46,XY DSD due to
5-α reductase type 2 deficiency. Am J Med Genet C
Semin Med Genet. 2017; 175(2): 260-267.
26. Houk CP, Lee PA. Consensus statement on terminology
and management: Disorders of sex development.
Sex Dev. 2008; 2(4-5): 172-180.
27. Wisniewski AB, Mazur T. 46,XY DSD with female or
ambiguous external genitalia at birth due to androgen
insensitivity syndrome, 5 α-reductase-2 deficiency,
or 17 β-hydroxysteroid dehydrogenase deficiency:
A review of quality of life outcomes. Int J Pediatr
Endocrinol. 2009; 2009: 567430.
28. Fenichel P, Paris F, Philibert P, Hieronimus S, Gaspari
L, Kurzenne JY, et al. Molecular diagnosis of
5 α-reductase deficiency in 4 elite young female
athletes through hormonal screening for hyperandrogenism.
J Clin Endocrinol Metab. 2013; 98(6):
E1055-E1059.
|
|
|
|
|
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|